The L3MBTL2 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function analysis of L3MBTL2, a polycomb group protein essential for chromatin compaction and transcriptional repression. This product offers a genetically disrupted pool of near-haploid HAP1 cells, providing a cost-effective and genetically tractable model for functional genomics and epigenetic studies. By ablating L3MBTL2 expression in a uniform haploid background, researchers can efficiently investigate its role in gene silencing without the complexity of diploid compensation.
HAP1 is a near-haploid adherent human cell line derived from the KBM-7 chronic myelogenous leukemia line, male origin, and characterized by a stable haploid karyotype. The haploid nature greatly simplifies CRISPR/Cas9-based gene disruption, because there is only one allele to target, ensuring that knockout alleles are not masked by wild-type copies. This makes HAP1 cells ideal for generating polyclonal knockout pools with high editing efficiency. Widely employed in genetic screens, functional genomics, and drug target validation, HAP1 cells serve as an optimal host for studying mammalian gene function in cancer and epigenetic contexts.
L3MBTL2 functions as a chromatin reader that specifically binds mono- and dimethylated histone H4 lysine 20 (H4K20me1/2) and histone H3 lysine 9 (H3K9me1/2), marks deposited by the histone methyltransferases SUV420H1/2 and SUV39H1/2. It is a core component of the non-canonical Polycomb repressive complex PRC1.6, cooperating with PCGF6, RING1B, E2F6, CBX7, and PHC1 to induce chromatin compaction and transcriptional silencing. This complex directly represses E2F target genes, including CCNA2 and CCNE1, placing L3MBTL2 downstream of the RB/E2F pathway and upstream of cell cycle control. Additionally, L3MBTL2 interacts with HP1 gamma, linking its function to chromocenter organization and heterochromatin maintenance.
Disrupting L3MBTL2 in the near-haploid HAP1 background eliminates allele redundancy, enabling unambiguous genotype-phenotype correlations in epigenetic and cancer biology studies. This polyclonal knockout model is particularly relevant for investigating PRC1.6-mediated gene silencing in hematopoietic malignancies and medulloblastoma, where L3MBTL2 is frequently implicated. It allows precise dissection of how L3MBTL2 loss alters chromatin states, global gene expression, and cell cycle progression, providing insights into tumor suppressive mechanisms and potential therapeutic vulnerabilities. Mutations or altered expression of L3MBTL2 have been associated with these malignancies, underscoring the model’s translational relevance.
Broad applications include functional genomics, epigenetic regulation, and cancer research, with utility in drug target validation. Representative techniques employed with this model include western blotting, RT-qPCR, chromatin immunoprecipitation (ChIP-qPCR), RNA-seq, chromatin compaction assays, proliferation assays, and cell cycle analysis. Co-immunoprecipitation and immunofluorescence enable interrogation of PRC1.6 complex integrity and subcellular localization. Drug sensitivity assays can be used to evaluate compounds targeting histone methylation pathways. For additional details or technical support, please contact Ascent Research.
